A Phase 4 interventional study of Control and NIMV group in Chronic Obstructive Pulmonary Disease and Hypercapnic, sponsored by Hospital Universitario La Paz. Recruiting at 1 site in Spain. Open to participants aged 45 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-03-06.
Sponsored by Hospital Universitario La Paz · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 309 studies in Pulmonary Disease, Chronic Obstructive with a site in Spain — 42 open to participants now, 45 under way, 9 of them phase 3. Pulmonary Disease, Chronic Obstructive · Spain.
Among the 309 studies in Pulmonary Disease, Chronic Obstructive with a site in Spain, this one is the 202nd largest by planned enrollment of the 238 interventional ones that give a count, is one of 19 that started in 2025, is one of 40 in phase 4, reaches primary completion later than 12 of the 44 other live ones, and was the 58th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →42 of the 309 studies in Pulmonary Disease, Chronic Obstructive with a site in Spain are open now. Recruiting first, the newest first:
Grifols Therapeutics LLC · Sites in Spain, United States, Denmark and 6 more countries
Ages 18–80
Aether Tech S.L. · Sites in Spain
Ages 40–90
Pfizer · Sites in Spain, United States, Argentina and 15 more countries
Ages 35–80
Clinica Universidad de Navarra, Universidad de Navarra · Sites in Spain
Ages 18+
GlaxoSmithKline · Sites in Spain, United States, Argentina and 22 more countries
Ages 40–75
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 45 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
309 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 33 · Phase 3 97 · Phase 4 40
First in 2000; this study’s year is marked. 19 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 336 across the 238 interventional studies, 254 across the 70 observational. Of the 217 that completed or were terminated, 112 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
169 of 309 have an industry lead sponsor. The 10 most frequent:
Hospital Universitario La Paz is the lead sponsor of 57 studies on the registry; 20 are open to participants now.
Hospital Universitario La Paz has 2 studies filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
12 of the studies in Pulmonary Disease, Chronic Obstructive with a site in Spain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
| NCT07555483Phase 3Grifols Therapeutics LLCA Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD) | 2027-09-30 |
| NCT07679646Air Liquide Healthcare SpainEffectiveness and Efficiency of Home Telemonitoring and Non-invasive Ventilation in Patients With COPD and Hypercapnia (EVALECO) | 2026-12 |
| NCT07432191Iconic Solutions By Murcia SLMedical Device Clinical Trial Without CE Marking to Evidence Safety and Performance of the INBENTUS VERSATILE Ventilator in Patients Requiring Assisted/Controlled Mechanical Ventilation and Weaning. | 2026-12 |
| NCT07938086Aether Tech S.L.Automated Oxygen Titration With the EMILY.AI Device During the Six-Minute Walk Test | 2026-12-20 |
Add all 12 to your calendar (.ics) → With an account.
Among the 309 studies in Pulmonary Disease, Chronic Obstructive with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Parallel, randomized and controlled clinical trial to evaluate the effect of 12 months of noninvasive mechanical ventilation versus conventional treatment in hypercapnic patients with stable COPD.
Main objective: To evaluate the effect of 12 months of noninvasive ventilation on c-reactive protein concentration and daily physical activity in hypercapnic patients with stable COPD.
Secondary objectives: To compare the plasmatic concentration of other inflammatory biomarkers between COPD patients with conventional treatment and wich noninvasive ventilation. To determine the response of breathlessness, health-related quality of life and lung function to noninvasive ventilation. To identify the COPD patients with a higher gasometric and clinic response to noninvasive ventilation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Conventional treatment for COPD
Drug: Control
NIMV: Conventional treatment plus noninvasive mechanical ventilation
Device: NIMV group
Current treatment according to the ATS/ERS guidelines
Also known as: Bronchodilator agents and inhaled corticosteroids
Current treatment according to the ATS/ERS guidelines and nocturnal BiPAP (IPAP 10-20 cmH2O,EPAP 4-6 cmH2O).
Also known as: Bronchodilator agents and inhaled corticosteroids.
daily physical activity and plasmatic concentration of C-reactive protein
Time frame: 12 months
Seric concentrations of homocysteine, proBNP, fibrinogen, cholesterol, tg, tnf-alpha, IL-1, IL-6 and 8-isoprostane
Time frame: 12 months
PaO2, PaCO2, pH, IC, VCIN, FVC, FEV1, FEV1/FVC, TLC, FRC/TLC, RV/TLC,PImax, PEmax, TTmus, 6MWD
Time frame: 12 months
BDI/TDI, SF-36, SGRQ, LCADL
Time frame: 12 months
Adverse effects
Time frame: 12 months
Cardiovascular effects, exacerbations, hospitalizations and mortality
Time frame: 12 months
Start is estimated for Dec 2025; primary completion for Dec 2025, 0 months later.
Of 86 non-industry phase 4 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 0 months is below that.
Counting every sponsor, half of 157 studies reached it within 19 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
Hospital Universitario La Paz